Table 2 Patterns of antidiabetic drug use for a group of patients with type 2 diabetes mellitus and chronic kidney disease in Colombia

Biguanides

 Metformin

67.3

1376.2 ± 631.7

1.5

49.6

74.5 ± 10.6

DPP4 inhibitors

52.2

52.9

74.7 ± 10.7

 Linagliptin

22

5.09 ± 0.67

1.01

57.5

75.2 ± 10.79

 Linagliptin/Metformin

4.6

5.09 / 1703.7 a

1.01

 Sitagliptin

8.8

90.3 ± 23.7

1.1

50.1

73.3 ± 10.1

 Sitagliptin/Metformin

10.1

90.3 / 1798.5 a

1.1

 Vildagliptin

4.5

83.7 ± 23.5

0.8

50.2

73.6 ± 10.6

 Vildagliptin/Metformin

5

83.7 / 1755.3 a

0.8

 Saxagliptin

0.5

5.04 ± 1.34

1

39.8

73.2 ± 10.2

 Saxagliptin/Metformin

1.8

5.04 / 1814.4 a

1

SGLT2 inhibitors

17.0

54.8

73.5 ± 11.4

 Empagliflozin

10.1

20.01 ± 7.3

1.14

57.4

71.2 ± 10.5

 Empagliflozin/Metformin

2.4

22.4 / 1755

1.28

 Empagliflozin/Linagliptin

0.3

18.4 / 5.5

1.05

 Dapagliflozin

3.6

10.6 ± 1.7

1.06

48.9

68.5 ± 10.4

 Dapagliflozin/Metformin

1.2

10.2 / 1593.2

1.02

 Canagliflozin

0.006

300 ± NA

1.5

0.0

68.0 ± NA

GLP-1 analogs

5.2

48.3

69.3 ± 10.5

 Liraglutide

4

1.74 ± 0.42

1.16

47.6

69.0 ± 10.5

 Dulaglutide (weekly)

0.8

2.54 ± 0.66 b

2.26

57.4

70.8 ± 9.8

 Exenatide (weekly)

0.5

2 ± NA

0.99

55.7

69.6 ± 10.3

 Semaglutide (weekly)

0.02

0.58 ± 0.38 b

0.77

66.7

64.0 ± 9.8

 Lixisenatide, mcg

0.02

20 ± NA

1

66.7

74.6 ± 5.0

Sulfonylureas

 Glibenclamide

1.4

7.3 ± 3.4

0.73

42.9

74.3 ± 10.0

 Glimepiride

1.1

3.2 ± 1.4

1.6

40.6

70.9 ± 10.4

 Gliclazide

0.6

66.0 ± 18.2

1.1

65.2

69.1 ± 10.5

Insulins (pooled)

 Long action analogs

32.3

NA

54.7

72.1 ± 11.3

 Fast action analogs

16.6

NA

54.7

71.1 ± 11.9

 NPH

1.7

NA

55.1

72.2 ± 11.8

 Crystal clear

0

NA

NA

NA